Deep vein thrombosis cost-effectiveness of therapy

Revision as of 18:16, 25 October 2011 by WikiBot (talk | contribs)
Jump to navigation Jump to search

Editors-in-Chief: C. Michael Gibson, M.S., M.D. Associate Editor-In-Chief: Ujjwal Rastogi, MBBS [1]

Deep Vein Thrombosis Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Deep vein thrombosis from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Approach

Assessment of Clinical Probability and Risk Scores

Assessment of Probability of Subsequent VTE and Risk Scores

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Venography

CT

MRI

Other Imaging Findings

Treatment

Treatment Approach

Medical Therapy

IVC Filter

Invasive Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Special Scenario

Upper extremity DVT

Recurrence

Pregnancy

Trials

Landmark Trials

Case Studies

Case #1

Deep vein thrombosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Deep vein thrombosis cost-effectiveness of therapy

CDC on Deep vein thrombosis cost-effectiveness of therapy

Deep vein thrombosis cost-effectiveness of therapy in the news

Blogs on Deep vein thrombosis cost-effectiveness of therapy

Directions to Hospitals Treating Deep vein thrombosis

Risk calculators and risk factors for Deep vein thrombosis cost-effectiveness of therapy

Overview

In United States, DVT and PE costs for

  • Initial hospitalization, average more than $9,800 and $14,000 respectively;
  • Rehospitalization costs average more than $11,800 and $14,700, respectively.

References

Template:WH Template:WS